

Reference Number: FOI202223/538
From: Commercial
Date: 18 January 2023
Subject: Biologic medicines in Dermatology

I have a freedom of information query regarding the use of Biologic medicines in Dermatology. Could you please answer the following three questions:

Q1 How many patients were treated in the last 3 months by the **Dermatology** department (for any medical condition) with the following biologic drugs:

- a. Adalimumab - Humira
- b. Adalimumab Biosimilar
- c. Apremilast
- d. Bimekizumab
- e. Brodalumab
- f. Certolizumab
- g. Dimethyl fumarate
- h. Etanercept - Enbrel
- i. Etanercept Biosimilar
- j. Guselkumab
- k. Infliximab - Remicade
- l. Infliximab Biosimilar
- m. Ixekizumab
- n. Risankizumab
- o. Secukinumab
- p. Tildrakizumab
- q. Ustekinumab

A1 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.

Q2 How many patients were treated in the last 3 months by the **Dermatology** department for Hidradenitis Suppurativa (HS) ONLY with the following biologic drugs:

- a. Adalimumab - Humira
- b. Adalimumab Biosimilar
- c. Infliximab - Remicade
- d. Infliximab Biosimilar
- e. Secukinumab
- f. Ustekinumab

A2 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following

medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.

- Q3 How many patients were treated in the last 3 months by the **Dermatology** department for Psoriasis ONLY in the last three months with the following:
- a. Ciclosporin
 - b. Methotrexate - any form and strength
 - c. Methotrexate injections 15mg and above
- A3 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.